« Return to News | CROs/Service Providers

ExecuPharm expands to U.K. and Argentina

Thursday, June 21, 2012 02:49 PM

ExecuPharm, a staffing and functional service providers (FSP) specializing solely in the clinical research industry, recently expanded its locations to include Europe and Latin America.

ExecuPharm’s new locations in Chichester, U.K., and Buenos Aries, Argentina, will allow the company to meet increasing client demand on a global scale. The two new locations will serve as regional headquarters to manage a network of localized professionals.

“The biggest driver for growing globally was client demand,” said Maria Larson , CEO of ExecuPharm. “ExecuPharm has a tried and tested model within the U.S. that is very robust and very effective. Because of our experience and success in the U.S., there was a desire to expand our tried and tested model into these markets.”

To manage the company’s global locations, ExecuPharm appointed Anthony Southers as general manager of global operations. Southers has 27 years of global clinical research experience, including pivotal roles in the creation of Innovex (currently known as Quintiles Innovex) and DOCS (an ICON staffing company.)

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.